Aldeyra Therapeutics
Small-molecule therapeutics targeting immune-mediated diseases
- Sector
- Biotech
- Headquarters
- LEXINGTON, MA
- Latest Form D
- $10M, Feb 2019
- Total capital
- $24.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $24.6M
- 4 Form D · last Feb 2019
- 92 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 20
- 20 pending · first 2021
- Rank in peer group#47 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$10M
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$7.8M
- Private capital raisedForm D · SEC · 1st filing$4.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#47 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Todd C. BradyResearcherExecutive Officer, DirectorLinked by 3 patents
- Ben J. BronsteinDirectorNamed in SEC Form D filings
- C. Boyd L. ClarkeDirectorNamed in SEC Form D filings
- C.Boyd C. ClarkeDirectorNamed in SEC Form D filings
- David L. ClarkExecutive OfficerNamed in SEC Form D filings
- David L. McMullinExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Gary J. PhillipsDirectorNamed in SEC Form D filings
- Jesse I. TreuDirectorNamed in SEC Form D filings
- Joshua ReedExecutive OfficerNamed in SEC Form D filings
- Martin J. JoyceDirectorNamed in SEC Form D filings
- Neal J. WalkerDirectorNamed in SEC Form D filings
- Richard I. DouglasDirectorNamed in SEC Form D filings
- Scott C. YoungExecutive OfficerNamed in SEC Form D filings
- Stephen I. MachathaExecutive OfficerNamed in SEC Form D filings
- Stephen C. TulipanoExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 20 granted of 40- PendingOphthalmic Formulations Of MethotrexateUSPTOApplication 19643612
- GrantedOphthalmic Formulations Of MethotrexateUSPTOUS 12,616,699
- PendingMethods Of Treating Sjögren-larssen SyndromeUSPTOApplication 18850826
Show all 40 patent records
- Ophthalmic Formulations Of MethotrexateAug 6, 2026 · Application 19643612Pending
- Ophthalmic Formulations Of MethotrexateMay 5, 2026 · US 12,616,699Granted
- Methods Of Treating Sjögren-larssen SyndromeJul 17, 2025 · Application 18850826Pending
- Compositions And Methods For The Treatment Of Macular DegenerationMay 8, 2025 · Application 18786975Pending
- Toxic Aldehyde Related Diseases And TreatmentApr 24, 2025 · Application 18904373Pending
- Deuterated Compounds And Uses ThereofMar 4, 2025 · US 12,240,816Granted
- Heterocyclic Aldehyde Trapping Compounds And Uses ThereofNov 21, 2024 · Application 18568566Pending
- Toxic Aldehyde Related Diseases And TreatmentOct 29, 2024 · US 12,128,013Granted
- Compositions And Methods For The Treatment Of Macular DegenerationSep 24, 2024 · US 12,097,188Granted
- Process For Preparation Of Aldehyde Scavenger And IntermediatesSep 24, 2024 · US 12,098,132Granted
- Pharmaceutical Formulations And Uses ThereofAug 20, 2024 · US 12,064,516Granted
- Polymorphic Compounds And Uses ThereofJul 9, 2024 · US 12,029,735Granted
- Methotrexate Treatment MethodsJun 20, 2024 · Application 18391167Pending
- Ophthalmic Formulations Of MethotrexateJun 11, 2024 · US 12,005,061Granted
- Polymorphic Compounds And Uses ThereofJun 11, 2024 · US 12,006,298Granted
- Ophthalmic Formulations Of MethotrexateJun 11, 2024 · US 12,005,060Granted
- Compositions And Methods Of Treating Retinal DiseaseMay 30, 2024 · Application 18341613Pending
- Ophthalmic Formulations And Uses ThereofMay 2, 2024 · Application 18367324Pending
- Methotrexate Treatment MethodsFeb 27, 2024 · US 11,911,385Granted
- Deuterated Compounds And Uses ThereofDec 19, 2023 · US 11,845,722Granted
- Ophthalmic Formulations And Uses ThereofOct 17, 2023 · US 11,786,518Granted
- Toxic Aldehyde Related Diseases And TreatmentOct 3, 2023 · US 11,771,664Granted
- Treatment Of Inflammatory DisordersSep 21, 2023 · Application 18202694Pending
- Compositions And Methods Of Treating Retinal DiseaseAug 15, 2023 · US 11,724,987Granted
- Treatment Of Inflammatory DisordersAug 10, 2023 · Application 18092758Pending
- Dry Eye Disease Biomarkers And Their Use For TreatmentJul 20, 2023 · Application 18007661Pending
- Toxic Aldehyde Related Diseases And TreatmentJul 18, 2023 · US 11,701,331Granted
- Quinoline Compounds For Treating Lung, Liver, And Kidney Diseases, Disorders, Or ConditionsMay 18, 2023 · Application 17918047Pending
- Quinoline Compounds For Treating Respiratory Disorders And Viral InfectionsApr 27, 2023 · Application 17914146Pending
- Treatment Of Inflammatory DisordersFeb 21, 2023 · US 11,583,529Granted
- Compositions And Methods Of Treating Retinal DiseaseFeb 9, 2023 · Application 17929273Pending
- Aldehyde Conjugates And Uses ThereofNov 10, 2022 · Application 17229797Pending
- Deuterated Compounds And Uses ThereofOct 4, 2022 · US 11,459,300Granted
- Treatment Of Dry Eye DiseaseJul 7, 2022 · Application 17654969Pending
- Combination Treatment Of Ocular Inflammatory Disorders And DiseasesJun 16, 2022 · Application 17448595Pending
- Formulations For Treatment Of Dry Eye DiseaseMay 5, 2022 · Application 17450623Pending
- Injectable FormulationsMay 5, 2022 · Application 17299731Pending
- Polymorphic Compounds And Uses ThereofApr 26, 2022 · US 11,312,692Granted
- Formulations For Treatment Of Dry Eye DiseaseDec 14, 2021 · US 11,197,821Granted
- Contact Lens Solutions And KitsOct 14, 2021 · Application 17282301Pending
Related companies, and why
- Elion TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Inductive Bio, Inc.Similar federal contract value in Biotech · null in contracts
- GB SCIENCES INCSimilar federal contract value in Biotech · null in contracts
- Thunder Biotech, Inc.Similar federal contract value in Biotech · null in contracts
- Trait Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Core Quantum Technologies, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .